A Phase 2, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular oedema (DME)
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2018
At a glance
- Drugs THR 317 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors ThromboGenics
- 16 Apr 2018 Status changed from active, no longer recruiting to completed.
- 04 Apr 2018 Results published in the ThromboGenics media release.
- 04 Apr 2018 According to a ThromboGenics media release, data for the anti-VEGF treatment naive group (n=40) up to Day 90 will be presented at an upcoming ophthalmology meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History